Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a Healthcare company (Biotechnology) with a market capitalization of $679M. The Maz Rating grades it against the other companies in its sector.
Attovia Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.86, Attovia Therapeutics, Inc. trades at 468.6x sales and 10.9x book value. Over the last twelve months it generated about $1M of revenue and a net loss of $83M. It runs a gross margin of 32.8%, an operating margin of -5945.5% and a net margin of -5477.2%. It shows return on equity of -58.9%, return on invested capital of -21.3% and a free cash flow yield of -11.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 34.66. Over the past 52 weeks the share price ranged from $12.94 to $28.00, with a beta of 0.00.
Attovia Therapeutics, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.